ZIAGEN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIAGEN is an oral small-molecule antiviral approved in 1998 for HIV treatment. The drug is a nucleoside reverse transcriptase inhibitor (NRTI) that works by blocking HIV replication. It is typically used as part of combination antiretroviral therapy.
$0.112MPart D
LOE ApproachingProduct is in advanced lifecycle stage with minimal Part D spending, indicating reduced market presence and smaller team requirements.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
ZIAGEN® Post-marketing Surveillance
Started Nov 2010
671 enrolled
Infection, Human Immunodeficiency Virus I
Career Relevance
Working on ZIAGEN offers minimal career growth given its LOE-approaching status and low commercial activity (0 linked jobs, $112K Part D spending). Roles focus on maintaining existing relationships and managing formulary access rather than driving revenue growth or innovation.
Field Sales Representative
Worked on ZIAGEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.